Eko Devices

Eko Devices

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Eko Devices is a private, commercial-stage medical device company founded in 2013 and headquartered in Oakland, California. It has successfully transitioned from a hardware innovator to an integrated AI-driven diagnostics platform, selling over 700,000 devices and securing nine FDA clearances. The company's core value proposition is increasing the accuracy and early detection of cardiovascular and pulmonary diseases by augmenting the traditional stethoscope exam with digital audio, visualization, and real-time AI analysis. Recent milestones include CMS reimbursement for its SENSORA® platform and validation in numerous clinical studies.

Cardiovascular DiseasePulmonary Disease

Technology Platform

Integrated platform combining digital stethoscope hardware (with enhanced audio and noise cancellation), visualization software (waveforms, 3-lead ECG), and FDA-cleared AI algorithms for real-time detection of cardiac conditions (murmurs, AFib, low ejection fraction). Supports telehealth integration and longitudinal data tracking.

Opportunities

The recent CMS reimbursement for its SENSORA platform in hospital outpatient settings opens a major new revenue channel and accelerates health system adoption.
Significant global opportunity exists in both developed markets for care standardization and in emerging markets with high disease burden and specialist shortages, as validated by recent studies.

Risk Factors

Future growth depends on navigating ongoing FDA regulatory pathways for new AI algorithms and expanding reimbursement beyond the initial CMS decision.
The company faces competition from other digital auscultation companies and must continuously prove the real-world clinical utility and cost-effectiveness of its AI to drive adoption in a conservative healthcare market.

Competitive Landscape

Eko competes with other digital stethoscope makers like 3M's Littmann CORE Digital, as well as broader cardiac diagnostic and monitoring companies (e.g., AliveCor, Butterfly Network). Its key differentiator is the deep integration of FDA-cleared, real-time AI analysis for specific pathologies directly into the auscultation workflow, creating a comprehensive decision-support platform rather than just a digital listening device.